---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-029193"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:02:51.666687+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# VYNE Therapeutics Q2 net loss $10.1M; VYN201 phase 1b data due Q3 2023

## Summary
- Net loss of $10.1M ($3.09 per share) vs $8.5M ($2.63) in Q2 2022; revenue flat at $0.1M.
- Cash and restricted cash $20.7M as of June 30, 2023; expects to fund operations through end of 2023.
- R&D expenses rose to $7.2M from $4.1M YoY, primarily due to VYN202 license payment and development costs.
- VYN201 Phase 1b preliminary safety/efficacy data in nonsegmental vitiligo anticipated in Q3 2023.
- VYN202 IND submission expected by year-end; Phase 1 trial to begin Q1 2024.

## SEC filing metadata
- accession: 0001628280-23-029193
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000162828023029193/0001628280-23-029193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000162828023029193/mnlo-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-029193
- JSON: https://secwatch.observer/filing/0001628280-23-029193.json
- Plain text: https://secwatch.observer/filing/0001628280-23-029193.txt

## Key facts
- Earnings Releases
  VYNE Therapeutics Inc. reported the three and six months ended June 30, 2023 results: net income Net loss and net loss per share for the quarter ended June 30, 2023 was $10.1 million and $3.09.
  - Period: the three and six months ended June 30, 2023
  - Net income: Net loss and net loss per share for the quarter ended June 30, 2023 was $10.1 million and $3.09
  - Result: reported results
  source text: VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2023 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000162828023029193/0001628280-23-029193-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.